Credit Suisse Group lowered shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a neutral rating to an underperform rating in a report released on Wednesday, MarketBeat.com reports. They currently have $13.00 price target on the stock, down from their previous price target of $25.00.

Other research analysts also recently issued reports about the company. Cantor Fitzgerald set a $31.00 price target on Teva Pharmaceutical Industries Limited and gave the company a hold rating in a report on Thursday, June 22nd. Vetr downgraded Teva Pharmaceutical Industries Limited from a hold rating to a sell rating and set a $31.05 price target for the company. in a report on Thursday, June 22nd. BidaskClub downgraded Teva Pharmaceutical Industries Limited from a sell rating to a strong sell rating in a report on Wednesday, August 16th. Citigroup Inc. downgraded Teva Pharmaceutical Industries Limited from a buy rating to a neutral rating and decreased their price target for the company from $32.00 to $19.00 in a report on Wednesday, August 16th. Finally, Maxim Group reissued a hold rating and issued a $35.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, July 13th. Four analysts have rated the stock with a sell rating, twenty have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of Hold and a consensus target price of $35.06.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 16.21 on Wednesday. Teva Pharmaceutical Industries Limited has a 52 week low of $15.85 and a 52 week high of $52.66. The stock’s market cap is $16.47 billion. The company’s 50-day moving average is $25.37 and its 200 day moving average is $30.35.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same period in the previous year, the firm posted $1.25 earnings per share. The company’s revenue was up 12.9% compared to the same quarter last year. On average, analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/27/teva-pharmaceutical-industries-limited-teva-rating-lowered-to-underperform-at-credit-suisse-group.html.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be issued a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 2.10%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is currently -14.22%.

A number of hedge funds have recently modified their holdings of TEVA. San Francisco Sentry Investment Group CA bought a new stake in shares of Teva Pharmaceutical Industries Limited during the second quarter valued at about $106,000. Bronfman E.L. Rothschild L.P. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter valued at about $123,000. Finally, Sterling Investment Advisors Ltd. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the last quarter. Institutional investors own 56.04% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.